IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

• Status: Completed
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The proposed Phase IIb clinical study aims to investigate the safety and efficacy of the active immunotherapy IMP321 in combination (adjunctive) with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Immutep S.A.; Immutep S.A.S.
• Collaborator: Prima BioMed Ltd
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

1. Able to give written informed consent and to comply with the protocol

2. Metastatic oestrogen receptor positive and/or progesterone receptor positive breast adenocarcinoma, histologically proven by biopsy of the primary tumour and/or metastasis

3. Female of age 18 years or above

4. Patients who are indicated to received first line chemotherapy with weekly paclitaxel

5. Evidence of measurable disease as defined by Response Evaluation Criteria version 1.1

6 Laboratory criteria: haematology and biochemistry results within the limits normally expected for the patient population.

Exclusion Criteria:

1. Prior chemotherapy for metastatic breast adenocarcinoma

2. Disease-free interval of less than twelve months from the last dose of adjuvant chemotherapy

3. Inflammatory carcinoma

4. Candidate for treatment with trastuzumab (or other Her2/neu targeted agents)

5. Systemic chemotherapy, radiation therapy or any other investigational agent within 4 weeks, endocrine therapy within 1 week prior to first dose of study treatment or CDK4/6 inhibitors within 5 times half-life (acc.to SPC) prior to first dose of study treatment and until completion of study treatment

6. Symptomatic known cerebral and/or leptomeningeal metastases

7. Serious intercurrent infection

8. Evidence of severe or uncontrolled cardiac disease (NYHA III-IV) within 6 months prior to first dose of study treatment

9. Active acute or chronic infection

10. Active autoimmune disease requiring immunosuppressive therapy

11. Previous malignancies within the last three years other than breast carcinoma

12. Patients with prior organ or stem cell transplantation

13. Any condition requiring continuous systemic treatment with either corticosteroids or other immunosuppressive medications within 4 weeks prior to first dose of study treatment.